Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee

for the WBMT and the CIBMTR Health Services and International Studies Committee

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

The current COVID-19 pandemic, caused by SARS-CoV-2, has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. Realizing the challenges as a result of this pandemic affecting the daily practice of the HCT centers and the recognition of the variability in practice worldwide, the Worldwide Network for Blood and Marrow Transplantation (WBMT) and the Center for International Blood and Marrow Transplant Research's (CIBMTR) Health Services and International Studies Committee have jointly produced an expert opinion statement as a general guide to deal with certain aspects of HCT, including diagnostics for SARS-CoV-2 in HCT recipient, pre- and post-HCT management, donor issues, medical tourism, and facilities management. During these crucial times, which may last for months or years, the HCT community must reorganize to proceed with transplantation activity in those patients who urgently require it, albeit with extreme caution. This shared knowledge may be of value to the HCT community in the absence of high-quality evidence-based medicine.

Original languageEnglish (US)
Pages (from-to)2181-2189
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume26
Issue number12
DOIs
StatePublished - Dec 2020

Bibliographical note

Funding Information:
Conflict of interest statement: M.K. has received honoraria from Gilead and Alexion. M.K.D. has served as a consultant for Pharmacyclics and Daiichi Sankyo. M.H. has received research support/funding from Takeda Pharmaceutical, Spectrum Pharmaceuticals, and Astellas Pharma; served as a consultant for Janssen R&D and Incyte; and served on the speaker's bureau for Sanofi Genzyme and AstraZeneca. D.W. reports research support from Incyte and consulting fees from FATE. S.H. reports honoraria and travel funding from Pfizer, Novartis, Gilead, Merck, Sanofi, Mallinckrodt, and Janssen. M.-A.P. has received honoraria from Abbvie, Bellicum, Celgene, Bristol-Myers Squibb, Incyte, Kite/Gilead, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda; has served on data safety and monitoring boards for Cidara Therapeutics, Servier, and Medigene and scientific advisory boards for MolMed and NexImmune; has received research support for clinical trials from Incyte, Kite/Gilead; and Miltenyi Biotec; and serves in a volunteer capacity as a member of the Board of Directors of Be The Match (National Marrow Donor Program), as well as on the CIBMTR Cellular Immunotherapy Data Resource Executive Committee. C.C. reports honoraria/travel funding from Astellas Pharma, Gilead, Merck, and Pfizer. A.W. has received research support from Ansun, WB Tech, Amazon and Allovir, and is a consultant for Kyorin.

Funding Information:
Financial disclosure:, Conflict of interest statement: M.K. has received honoraria from Gilead and Alexion. M.K.D. has served as a consultant for Pharmacyclics and Daiichi Sankyo. M.H. has received research support/funding from Takeda Pharmaceutical, Spectrum Pharmaceuticals, and Astellas Pharma; served as a consultant for Janssen R&D and Incyte; and served on the speaker's bureau for Sanofi Genzyme and AstraZeneca. D.W. reports research support from Incyte and consulting fees from FATE. S.H. reports honoraria and travel funding from Pfizer, Novartis, Gilead, Merck, Sanofi, Mallinckrodt, and Janssen. M.-A.P. has received honoraria from Abbvie, Bellicum, Celgene, Bristol-Myers Squibb, Incyte, Kite/Gilead, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda; has served on data safety and monitoring boards for Cidara Therapeutics, Servier, and Medigene and scientific advisory boards for MolMed and NexImmune; has received research support for clinical trials from Incyte, Kite/Gilead; and Miltenyi Biotec; and serves in a volunteer capacity as a member of the Board of Directors of Be The Match (National Marrow Donor Program), as well as on the CIBMTR Cellular Immunotherapy Data Resource Executive Committee. C.C. reports honoraria/travel funding from Astellas Pharma, Gilead, Merck, and Pfizer. A.W. has received research support from Ansun, WB Tech, Amazon and Allovir, and is a consultant for Kyorin. Financial disclosure: See Acknowledgments on page 2188.

Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy

Keywords

  • COVID-19
  • Pandemic
  • Stem cells
  • Transplantation
  • SARS-CoV-2
  • Humans
  • Bone Marrow Transplantation
  • Hematopoietic Stem Cell Transplantation
  • COVID-19/diagnosis

PubMed: MeSH publication types

  • Practice Guideline

Fingerprint

Dive into the research topics of 'Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee'. Together they form a unique fingerprint.

Cite this